search
Back to results

Lipoprotein Subfractions and Coronary Heart Disease During 25 Year Follow-up

Primary Purpose

Cardiovascular Diseases, Heart Diseases, Coronary Disease

Status
Completed
Phase
Locations
Study Type
Observational
Intervention
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Cardiovascular Diseases

Eligibility Criteria

undefined - 100 Years (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

No eligibility criteria

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    May 25, 2000
    Last Updated
    February 26, 2016
    Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00005215
    Brief Title
    Lipoprotein Subfractions and Coronary Heart Disease During 25 Year Follow-up
    Study Type
    Observational

    2. Study Status

    Record Verification Date
    May 2000
    Overall Recruitment Status
    Completed
    Study Start Date
    April 1988 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    March 1992 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    5. Study Description

    Brief Summary
    To determine the relationship of fatal and nonfatal coronary heart disease to lipoprotein fractions and other risk factors in a prospective epidemiologic study conducted between 1954 and 1957.
    Detailed Description
    BACKGROUND: Prospective epidemiologic studies of cholesterol, blood pressure, and cigarette use have provided much of the evidence linking these established risk factors to coronary heart disease, for example the Framingham Study, the Western Electric Study, and the Chicago Peoples Gas Company Study. Concurrent to these well known studies, was an effort by Dr. John Gofman to measure lipoprotein subfraction concentrations in 2,880 male and female employees of the Lawrence Livermore National Laboratory, and to establish prospectively the associations of HDL2, HDL3, LDL, IDL, smaller VLDL and larger VLDL to coronary heart disease. After 10 years of follow-up, Dr. Gofman presented his findings at the Lyman Duff Memorial Lecture on October 13, 1965. The findings were subsequently published in Circulation in 1966. He reported an increased risk of coronary heart disease in association with high serum mass concentrations of LDL, IDL, and smaller VLDL and low concentrations of HDL2 and HDL3. This pioneering effort by Dr. Gofman preceded the recognition of the importance of lipoprotein subfractions by nearly a decade, so that more detailed statistical analyses and further follow-up of the cohort were deferred indefinitely. Most importantly, in 1952 Gofman used essentially the same methodology to measure lipoprotein subfractions that was in practice in 1988 at the Donner Laboratory for numerous in-house and collaborative studies including the study of atherosclerotic progression in the Stanford Coronary Risk Intervention Project, the effects of exercise and weight loss on lipoproteins in the Stanford Exercise Training Study and Weight Control Projects, and metabolism and genetic transmission as part of the Donner Laboratory NIH program project entitled Lipoprotein Subclasses: Structure, Origin and Metabolism. DESIGN NARRATIVE: Serum lipoprotein subfraction concentrations were measured in 1,961 men and 423 women who were employed or who applied for employment at Lawrence Livermore National Laboratory between 1954 and 1957. Computer files were created by Dr. Gofman at Donner Laboratory for epidemiologic studies of lipoprotein fractions. The files included name, age, gender and the following medical information: cholesterol, lipoprotein subfraction concentrations, blood pressure, weight, smoking history, hemoglobin, red and white blood cell counts, and blood proteins. Dr. Gofman provided those computer files for this study. The vital status and the history of coronary disease in the cohort were determined through state and national mortality surveillance systems, public records, medical and hospital records, autopsy reports, and telephone interviews with cohort members. All medical documents were examined by a physician and endpoints assigned according to international diagnostic criteria. The data were used to extend Dr. Gofman's initial study from 10 to 30 years of follow-up. Survival analysis was used to assess the independent contributions of specific lipoprotein subclasses to coronary disease while controlling for other risk factors. Other issues examined were whether HDL2 and HDL3 showed different relationships to coronary disease, whether the relationships of lipoprotein subfractions to coronary disease were independent of other established risk factors, and whether measurements of lipoprotein subfraction concentrations offered significant improvement over total cholesterol in predicting coronary disease risk. The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cardiovascular Diseases, Heart Diseases, Coronary Disease

    7. Study Design

    10. Eligibility

    Sex
    Male
    Maximum Age & Unit of Time
    100 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    No eligibility criteria

    12. IPD Sharing Statement

    Learn more about this trial

    Lipoprotein Subfractions and Coronary Heart Disease During 25 Year Follow-up

    We'll reach out to this number within 24 hrs